MedPulser

MedPulser™

A device for delivering electroporation-enhanced delivery of drugs, DNA vaccines and gene therapies intended to treat cancer, infectious diseases and other medical conditions.

Adverse effects
Pain, occurring within five minutes of electroporation.
References in periodicals archive ?
The ChronVac-C DNA vaccine delivered by in vivo electroporation using the Medpulser was recently reported to be safe and generate antigen specific immune responses as well as antiviral effects in a Phase I/IIa clinical trial.
The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Delivery System.
Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems.
Based on the promising results from patients with chronic hepatitis C virus infection who after vaccination with ChronVac-C delivered by Inovios Medpulser DDS underwent standard-of-care treatment, ChronTech filed applications to start a Phase IIb clinical trial.
In the Phase IIb clinical study patients with genotype 1 chronic hepatitis C will be grouped to receive, or not to receive, two vaccinations with ChronVac-C delivered by Inovios Medpulser DDS immediately followed by standard-of-care treatment with ribavirin and interferon.
Inovio is moving its lead product, the MedPulser, through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation; a U.
Inovio Biomedical Corporation today announced that its partner, Tripep AB of Sweden, recently demonstrated that Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Drug Delivery System, activated a T-cell response in mice that appears capable of clearing liver cells expressing hepatitis C virus protein in a murine model of hepatitis C.
The data was obtained in support of a planned application for a clinical trial designed to test the therapeutic use of the combination of the ChronVac-C DNA vaccine and Inovio's MedPulser gene delivery system in chronic hepatitis C infections.